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Abstract
AIM
To evaluate toxicity and treatment outcome of high-
dose radiotherapy (RT) for cervical esophageal cancer 
(CEC).
METHODS
We reviewed a total of 62 consecutive patients who 
received definitive RT for stage Ⅰ to Ⅲ cervical 
esophageal cancer between 2001 and 2015. Patients 
who received < 45 Gy, treated for lesions below 
sternal notch, treated with palliative aim, treated 
with subsequent surgical resection, or diagnosed with 
synchronous hypopharyngeal cancer were excluded. 
Treatment failures were divided into local (occurring 
within the RT field), outfield-esophageal, and regional 
[occurring in regional lymph node(s)] failures. Factors 
predictive of esophageal stenosis requiring endoscopic 
dilation were analyzed.
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RESULTS
Grade 1, 2, and 3 esophagitis occurred in 19 (30.6%), 
39 (62.9%), and 4 patients (6.5%), respectively, 
without grade ≥ 4 toxicities. Sixteen patients (25.8%) 
developed post-RT stenosis, of which 7 cases (43.8%) 
were malignant. Four patients (6.5%) developed 
tracheoesophageal fistula (TEF), of which 3 (75%) 
cases were malignant. Factors significantly correlated 
with post-RT stenosis were stage T3/4 (P  = 0.001), 
complete circumference involvement (P  < 0.0001), 
stenosis at diagnosis (P  = 0.024), and endoscopic 
complete response (P  = 0.017) in univariate analysis, 
while complete circumference involvement was signifi-
cant in multivariate analysis (P  = 0.003). A higher dose 
(≥ 60 Gy) was not associated with occurrence of post-
RT stenosis or TEF. With a median follow-up of 24.3 
(range, 3.4-152) mo, the 2 y local control, outfield eso-
phageal control, progression-free survival, and overall 
survival (OS) rates were 78.9%, 90.2%, 49.6%, and 
57.3%, respectively. Factors significantly correlated 
with OS were complete circumference involvement 
(P  = 0.023), stenosis at diagnosis (P  < 0.0001), and 
occurrence of post-RT stenosis or TEF (P  < 0.001) in 
univariate analysis, while stenosis at diagnosis (P  = 
0.004) and occurrence of post-RT stenosis or TEF (P  = 
0.023) were significant in multivariate analysis. 
CONCLUSION
Chemoradiation for CEC was well tolerated, and a 
higher dose was not associated with stenosis. Patients 
with complete circumferential involvement require close 
follow-up.
Key words: Chemoradiotherapy; Post-radiotherapy 
stenosis; High-dose radiotherapy; Cervical esophageal 
cancer
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Core tip: This study reports the outcome and toxicity 
of high dose (median 63 Gy) radiotherapy for cervical 
esophageal cancer. Post-RT stenosis and tracheoeso-
phageal fistula rates were 26% and 6.5%, respectively. 
Stenosis at diagnosis and post-RT stenosis/fistula was 
significantly associated with overall survival. Complete 
circumference involvement was significantly associated 
with post-RT stenosis but dose higher than 60 Gy was 
not.
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INTRODUCTION
Carcinoma of the cervical esophagus is uncommon and 
accounts for 2%-10% of all esophageal carcinomas[1]. 
Squamous cell carcinoma (SCC) is predominant in the 
proximal esophagus, and the highest rates of SCC are 
found in East Asia and Southern Africa[2]. There are 
no prospective clinical trials to establish the standard 
care for cervical esophageal cancer (CEC). Because 
CEC is located between the cricopharyngeal muscle 
and the sternal notch, the surgical procedure to CEC is 
extensive, such as pharyngo-laryngo-esophagectomy[3], 
resulting in permanent tracheostomy and significant 
deterioration of quality of life[4]. Concurrent chemo-
radiotherapy (CRT) has emerged as the preferred 
treatment modality for CEC[5]. Common toxic effects of 
definitive CRT for CEC include dysphagia, dehydration, 
mucositis, esophagitis, dermatitis, and fatigue[6]. Late 
toxic effects, such as stricture and fistulas may also 
occur[7,8].
Because of its anatomical proximity to the hypoph-
arynx, CRT protocols for CEC are somewhat analog-
ous to those for hypopharyngeal cancer[6]. However, 
unlike locally advanced SCC of the hypopharynx which 
requires 70 Gy in 35 fractions for definitive CRT[9], the 
standard dose of CRT for esophageal cancer remains 
50 Gy[5,10]. Although a higher-than-standard dose of 50 
Gy is suggested for CEC[5], the increased dose to the 
esophagus may lead to a higher incidence of severe 
toxicities, including ulcer, perforation, and stenosis[11]. 
Organs at risk for RT planning depend on the site of 
treatment. Radiation pneumonitis and fibrosis are of 
major concern when planning for the thoracic esophagus 
but are of less importance for CEC. Esophageal toxicity 
information from hypopharyngeal cancer treatment is 
of limited value; the radiation field for hypopharyngeal 
cancer includes only a small segment of the cervical 
esophagus, while RT for CEC includes a large segment 
of the esophagus because of expansion of the cranioca-
udal margins from the gross tumor and the entire 
esophageal circumference. Reports on the high-dose 
radiation-induced toxicity of CEC are scarce, although 
information can be inferred from the retrospective data 
on head and neck cancer patients experiencing toxicities 
of the proximal esophagus[12]. A toxicity evaluation is 
required before the administration of dose-escalated 
protocols.
We report the outcome and toxicity of definitive 
radiotherapy (RT) for CEC, with an emphasis on the 
identification of clinical variables associated with the 
occurrence of post-RT esophageal stenosis and tracheo-
esophageal fistulas (TEF).
MATERIALS AND METHODS
Patients
We retrospectively reviewed a total of 62 consecutive 
patients who received definitive RT for pathologically 
confirmed stage Ⅰ-Ⅲ (American Joint Committee 
on Cancer 7th edition) CEC between 2001 and 2015. 
CEC was defined as a tumor of the esophagus located 
between the inferior border of the cricoid cartilage and 
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the thoracic inlet (suprasternal notch). Tumors with 
the epicenter located below the sternal notch were 
generally considered non-CEC for this study. Patients 
treated with a palliative aim, those who received < 45 
Gy, those treated with subsequent surgical resection, 
or those diagnosed with synchronous hypopharyngeal 
cancer were excluded. All procedures were performed 
in accordance with the Helsinki Declaration of 1975, 
as revised in 1983. This study was approved by the 
institutional review board (4-2017-0027).
Treatment
All patients were treated according to institutional 
protocols, consisting of platinum-based concurrent CRT 
or RT alone if patients could not tolerate chemotherapy. 
The gross tumor volume (GTV) was defined as a visible 
tumor in the esophagus and gross regional lymph node 
metastasis. The initial clinical target volume (CTV1) was 
defined by expansion of the GTV by 4 cm craniocaudally 
and 1-2 cm laterally, as well as bilateral supraclavicular 
lymph nodes inclusion for elective nodal irradiation. The 
initial planning target volume (PTV1) was defined as 
CTV1 plus a 0.5 cm margin in all directions, and 36-45 
Gy in a conventional daily fractionation of 1.8 Gy was 
prescribed for PTV1. The boost CTV (CTV2) included 
the GTV plus a 3-4 cm craniocaudal margin and a 1-2 
cm lateral margin, excluding the elective nodal field. 
PTV2 was obtained by adding a 0.5 cm margin to CTV2 
in all directions and received a total dose of up to 50.4 
Gy, while limiting the maximum spinal cord dose under 
45 Gy. For patients receiving a total dose higher than 
50.4 Gy, an additional boost dose was delivered to 
PTV3, which comprised the GTV with a narrow margin 
of 0.5-1 cm in all directions. Cisplatin (or carboplatin) 
and 5-fluorouracil (5-FU) based chemotherapy was 
used. Two cycles of chemotherapy were administered 
concurrently with RT, followed by 1-6 cycles of 
consolidation chemotherapy[13].
Follow-up and evaluation
Upon completion of concurrent CRT, patients were 
evaluated every 3 mo for the first year and every 6 
mo thereafter with a physical examination, toxicity 
assessment, upper gastrointestinal endoscopy, com-
puted tomography (CT) scans of the neck, chest, and 
abdomen, and, when necessary, positron emission 
tomography-CT. Acute and late toxicity was assessed 
using the Radiation Therapy Oncology Group (RTOG) 
criteria. Esophageal stenosis was evaluated using 
esophagography or endoscopy, and significant sten-
osis was defined as symptomatic stenosis requiring 
endoscopic dilatation and/or stent insertion. Endoscopic 
complete remission (CR) of the primary tumor was 
defined when all visible tumors disappeared on 
endoscopy and a negative biopsy was conducted, with 
these outcomes lasting for more than 4 wk. Treatment 
failures were divided into local (occurring within the RT 
field), outfield-esophageal, and regional [occurring in 
regional lymph node(s)] failures. Factors predictive of 
esophageal stenosis requiring endoscopic dilation and 
TEF were analyzed.
Statistical analysis
Survival time was measured from the date of diagnosis 
to the date of the first event or the date of death. 
Survival curves were estimated using the Kaplan-Meier 
method, and multivariate analysis was performed 
using the Cox proportional hazard model. Correlation 
between clinical variables and post-RT occurrence of 
esophageal stenosis/TEF was performed using the 
χ 2 test. A P value < 0.05 was indicative of statistical 
significance.
RESULTS
Patient characteristics
The median age was 66 (range, 29-86) years, and SCC 
was predominant (90.3%). The numbers of patients 
with T1, T2, T3, and T4 disease were 14 (22.6%), 6 
(9.7%), 30 (48.4%), and 12 (19.3%), respectively. The 
median length of tumor involvement of the esophagus 
was 5.0 (range, 1-14) cm, and 22 patients had a tumor 
involving 100% of the esophageal circumference. 
The median biologically equivalent RT dose in 1.8-Gy 
fraction was 63 (range, 45-90) Gy. Two of the patients 
received a total dose of 81 Gy and 90 Gy each because 
a boost RT (18-27 Gy) was delivered to the residual 
tumor 1-2 mo after 63 Gy. Sixty patients (96.8%) were 
treated with concurrent chemotherapy (Table 1).
Toxicity and risk factors
Grade 1, 2, and 3 esophagitis occurred in 19 (30.6%), 
39 (62.9%), and 4 patients (6.5%), respectively, 
without grade 4 or 5 toxicities. Sixteen patients 
(25.8%) developed stenosis requiring dilation within 
a median of 5.5 mo (range 1.1-22.5) after RT, among 
which 7 cases (11.3%) were malignant strictures. 
Four patients (6.5%) developed TEF within a median 
of 2.6 mo (range 1.8-5.8) after RT, 3 (4.8%) of which 
were malignant fistulas (Table 2). Factors showing a 
significant correlation with post-RT stenosis requiring 
dilation were T3/4 disease (vs T1/2) (P = 0.001), 
100% circumference involvement (vs < 100%) (P < 
0.0001), stenosis at diagnosis (vs none) (P = 0.024), 
and endoscopic CR (vs < CR) (P = 0.017) in univariate 
analysis. A higher dose (≥ 60 Gy) was not associated 
with post-RT stenosis (P = 0.515). Only 100% 
circumference involvement was significantly associated 
with stenosis in multivariate analysis (P = 0.003) 
(Table 3). Factors showing significant correlation with 
either post-RT stenosis requiring dilatation or TEF were 
T3/4 (vs T1/2) (P < 0.0001), 100% circumference 
involvement (vs < 100%) (P < 0.0001), stenosis at 
diagnosis (vs none) (P = 0.023), and endoscopic CR 
(vs < CR) (P = 0.001) in univariate analysis. Higher 
dose (≥ 60 Gy) was not associated with post-RT 
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patients (Supplementary Table 2).
Treatment outcome and prognostic factors
Twenty-seven patients were alive at the time of 
diagnosis. The median follow-up was 24.3 (range, 
3.4-152) mo for all patients and 67.8 (range, 17.8-152) 
mo for surviving patients. An endoscopic CR was 
achieved in 39 patients (62.9%). A total of 34 patients 
experienced treatment failures: 7 local, 3 outfield 
esophageal, 6 regional, 11 distant, 2 concurrent local and 
regional, 1 concurrent outfield esophageal and regional, 
3 concurrent local and distant, and 1 concurrent outfield 
esophageal, regional, and distant failure (Supplementary 
figure 1). The 2-year local failure-free (LFFS), outfield 
esophageal failure-free, regional failure-free, distant 
metastasis-free, progression-free, and overall survival 
(OS) rates were 78.9%, 90.2%, 79.5%, 72.7%, 49.6%, 
and 57.3%, respectively. T3/4 stage (P = 0.050), 
stenosis at diagnosis (P = 0.025), and RT stenosis or 
TEF (P = 0.001) showed a correlation with LFFS in 
univariate analysis. Only the occurrence of RT stenosis 
stenosis or TEF (P = 0.259). Both 100% circumfer-
ence involvement (P = 0.002) and endoscopic CR 
(P = 0.035) were significantly associated with the 
occurrence of post-RT stenosis or TEF in multivariate 
analysis (Supplementary Table 1). Table 4 summarizes 
the clinical variables and treatment outcomes among 
the 19 patients who developed post-RT stenosis 
requiring dilatation or TEF. Nine of these patients had 
endoscopic findings of total esophageal obstruction at 
the time of diagnosis and 10 patients had dysphagia 
symptoms only. Seven of the 8 patients (87.5%) who 
developed non-malignant post-RT stenosis and 5 of 
the 7 patients (71.4%) who developed malignant 
post-RT stenosis initially had 100% circumferential 
esophageal involvement by the tumor. Four patients 
with post-RT TEF showed a CR or partial response (PR) 
and developed fistulas within 6 mo after completion 
of RT. Of the 17 patients who initially had endoscopic 
finding of total obstruction at the time of diagnosis, 
post-RT stenosis requiring dilatation was reported in 8 
patients (3 malignant stenosis) and malignant TEF in 2 
Table 1  Demographic and treatment data (n  = 62)
Characteristics n  (%)
Sex Female:Male 4:58 (6.5:93.5)
Age Median 66 yr (range 29-86)
Pathology Squamous cell carcinoma 56 (90.3)
Adenocarcinoma 2 (3.2)
Other 4 (6.5)
T stage T1 14 (22.6)
T2 6 (9.7)
T3 30 (48.4)
T4 12 (19.3)
Regional node metastasis N0 14 (22.6)
N+ 48 (77.4)
Tumor length Median 5.0 cm (range 1-14)
Total length of skip lesions Median 5.0 cm (range 1-20)
Involved circumference < 100% 40 (64.5)
100% 22 (35.5)
Stenosis at diagnosis No 45 (72.6)
Yes 17 (27.4)
Radiation dose (EQD1.8) Median 63 Gy (range 45-90)
Concurrent chemotherapy Yes 60 (96.8)
No 2 (3.2)
Endoscopic response CR 39 (62.9)
< CR 23 (37.1)
EQD1.8: Biologically equivalent dose in 1.8 Gy fractions; CR: Complete response.
Table 2  Post-radiotherapy toxicity profile
Toxicity n  (%) RT-event interval (mo)
Esophagitis RTOG Gr 1 19 (30.6)
RTOG Gr 2 39 (62.9)
RTOG Gr 3 4 (6.5)
RT stenosis1 All 16 (25.8) Median 5.5 (range 1.1-22.5)
Malignant 7 (11.3)
T-E fistula All 4 (6.5) Median 2.6 (range 1.8-5.8)
Malignant 3 (4.8)
1Stenosis requiring dilatation. RTOG: Radiation therapy oncology group; T-E: Tracheoesophageal; Gr: Grade; RT: Radiotherapy.
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or TEF showed a trend towards poor LFFS in multivariate 
analysis (P = 0.066) (Supplementary Table 3 and Figure 
1A). Factors showing significant correlations with OS 
were 100% circumference involvement (P = 0.023), 
stenosis at diagnosis (P < 0.0001), and occurrence 
of radiation induced stenosis or TEF (P < 0.001) in 
univariate analysis. Both stenosis at diagnosis (P = 0.004) 
and occurrence of RT stenosis or TEF (P = 0.023) were 
significantly associated with OS in multivariate analysis 
(Supplementary Table 4 and Figure 1B). 
DISCUSSION
The most common radiation-induced late esophageal 
Table 3  Factors influencing occurrence of post-radiotherapy stenosis n  (%)
Characteristics No. of Patients Stenosis P  value
No Yes Univariate Multivariate
Age
   ≤ 65 30 24 (80) 6 (20) 0.236
   > 65 32 22 (69) 10 (31)
T stage
   T1/2 20 20 (100) 0 0.001 0.998
   T3/4 42 26 (62) 16 (38)
Involved circumference
   < 100% 40 37 (93) 3 (7) < 0.0001 0.003
   100% 22 9 (41) 13 (59)
Total length
   < 5.0 28 22 (79) 6 (921) 0.338
   ≥ 5.0 34 24 (71) 10 (29)
Stenosis at diagnosis
   No 45 37 (82) 8 (18) 0.024 0.995
   Yes 17 9 (53) 8 (47)
Dysphagia at diagnosis
   ≤ 1 mo 36 30 (83) 6 (17) 0.051
   > 1 mo 26 16 (62) 10 (38)
RT dose
   ≥ 60 Gy 37 27 (73) 10 (27) 0.515
   < 60 Gy 25 19 (76) 6 (24)
Endoscopic response
   CR 39 33 (85) 6 (15) 0.017 0.740
   < CR 23 13 (56) 10 (44)
RT: Radiotherapy; CR: Complete response.
Table 4  Patients with post-radiotherapy stenosis or tracheoesophageal fistula (n  = 19)
Age/Sex T stage Involve circumf Initial stenosis/ management RT (Gy) Response Toxicity (onset, mo) Outcome (mo)
29/F T3 100% Dysphagia only 59.4 CR Stenosis (20) NED, alive (152)
70/M T3 100% Total obst/none 59.4 PR Stenosis (5) DOOC (12)
64/M T4a 100% Dysphagia only 63.0 PR Stenosis (1) DM (5), DOD (7)
68/F T3 100% Dysphagia only 63.0 CR Stenosis (1) NED, alive (21)
75/M T3 100% Total obst/none 63.0 PR Stenosis (2) DOOC (22)
60/F T4b 100% Total obst/stent 70.0 CR Stenosis (4) NED, alive (23)
68/M T3 100% Dysphagia only 70.2 SD Stenosis (6) InF (8), DOD (14)
73/M T4b 75% Total obst/stent 90.01 PR Stenosis (11) DM (13), DOD (17)
64/M T3 100% Dysphagia only 50.4 PR Stenosis2 (9) InF (17), DOD (20)
69/M T4b 100% Total obst/stent 50.4 SD Stenosis2 (2) DOOC (5)
64/M T4a 100% Dysphagia only 59.4 PR Stenosis2 (7) DM (3)/InF (9), DOD (11)
68/M T3 100% Total obst/none 63.0 PR Stenosis2 (2) DM (3), DOD (5)
73/M T3 100% Total obst/PEG 63.0 PR Stenosis2 (22) InF (16), DOD (31)
75/M T3 40% Dysphagia only 57.6 CR Stenosis2 (14) InF (7), DOD (31)
74/M T3 50% Dysphagia only 81.01 CR Stenosis2 (9) InF (9), DOD (16)
57/M T3 100% Dysphagia only 63.0 PR TEF (3) OutF (8), DOD (9)
57/M T3 100% Total obst/stent 60.0 CR Stenosis (1)/TEF2 (6) InF (8), DOD (14)
72/M T3 100% Total obst/stent 63.0 PR TEF2 (2) DOOC (5)
51/M T3 40% Dysphagia only 63.0 PR TEF2 (2) RF (4), DOD (6)
1Boost RT (18-27 Gy) was delivered to residual tumor 1-2 mo after 63 Gy. 2Malignant complications. Involve circumf: Percent of esophageal circumference 
involved by tumor; RT: Radiotherapy; obst: Obstruction; PEG: Percutaneous endoscopic gastrostomy; CR: Complete response; PR: Partial response; SD: 
Stable disease; InF: Infield failure; OutF: Outfield failure; RF: Regional failure; DM: Distant metastasis; DOD: Died of disease; DOOC: Died of other cause; 
NED: No evidence of disease; TEF: Tracheoesophageal fistula.
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toxicity is dysphagia due to dysmotility and esophageal 
stricture[14], and these complications can result from 
muscular damage, submucosal fibrosis, and possibly 
nerve damage[15]. Unlike the lower esophagus, the 
proximal esophagus is composed predominantly of 
striated muscles, and conscious, voluntary swallowing 
is the key function in this part of the organ. Thus, 
stricture after RT rather than impaired peristalsis and 
involuntary swallowing may be the main cause of 
dysphagia in the cervical esophagus.
Toxicity evaluation of higher-than-standard-dose 
RT for CEC was necessary, and the primary objective 
of the current study was to determine clinical factors 
associated with the development of post-RT stenosis 
and TEF. Although most of the patients (96.8%) were 
treated with standard cisplatin and 5-FU-based CRT, 
the radiation dose used for the current study, at a 
median of 63 (range, 45-90) Gy, was significantly 
higher than the standard dose of 50 Gy. In the current 
study, preservation of the esophageal passage, either 
pre-RT (at diagnosis) stenosis (P = 0.004) or post-
RT stenosis/TEF (P = 0.023), was an independent 
prognostic factor associated with OS, suggesting that 
resolution of the initial stenosis and prevention of post-
treatment stenosis are indeed important in prolonging 
patients’ survival.
The esophagus is a hollow viscous organ with a 
tubular structure and it functions in series, such that 
destruction of the complete circumference of a small 
volume of esophagus could result in dysfunction of 
the entire organ. Unlike treating head and neck or 
lung cancers, full circumferential treatment of the 
esophagus cannot be avoided when treating tumors 
originating in the esophagus. Maguire et al[16] observed 
that patients who received > 80 Gy to any portion 
of the entire organ circumference had an increased 
risk of late toxicity in multivariate analysis. Although 
a higher dose to the esophagus increases the risk of 
severe complications, the application of more than 50 
Gy may improve local control. In the current study, the 
highest dose we prescribed was 63 Gy except for the 
2 patients who received a boost dose of 18 Gy and 27 
Gy to the residual tumor. Although this is not a dose-
escalation study, 63 Gy may be safely delivered to the 
cervical esophagus without causing severe toxicities.
It should be noted that, while 16 patients (25.8%) 
developed post-RT stenosis requiring dilation and 4 
patients (6.5%) developed TEF, 7 (44%) and 3 (75%) 
patients were because of persistent or recurrent 
malignancy, respectively. Clinically diagnosed post-RT 
stricture may grossly overestimate the risk of radiation 
induced stenosis and may be an early sign of tumor 
recurrence[17]. In fact, only complete circumferential 
tumor involvement was an independent predictor of 
post-RT stenosis, while T stage, stenosis at diagnosis, 
and a higher dose (≥ 60 Gy) were not (Table 3). 
When both post-RT stenosis and TEF were consider-
ed, complete circumference tumor involvement and 
endoscopic CR were both independent predictors 
(Supplementary Table 1). Considering that 75% of TEF 
cases were malignant and occurred within the first 6 
mo after completion of RT and after achieving a CR 
or PR, a rapid response to CRT, rather than a higher 
radiation dose, may be a contributing factor to the 
development of post-RT TEF.
A study by Atsumi et al[18] suggested that esoph-
ageal stenosis is associated with tumor regression after 
RT. In this study, 109 patients who achieved a CR after 
definitive CRT were evaluated with esophagography 
within 3 mo after completion of RT; and T stage, 
extent of involved circumference, and wall thickness 
of the tumor region were significantly correlated with 
esophageal stenosis in multivariate analysis[18]. Luminal 
narrowing of the esophagus after RT is largely due 
to fibrosis and inflammation of the submucosal and 
muscular layers[19,20]. These processes accompany 
infiltration of inflammatory cells[21] and probably include 
accumulation of macrophages with increased local levels 
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Figure 1  Comparison of local failure-free survival (A) and overall survival (B) between patients who experienced post-radiotherapy stenosis or 
tracheoesophageal fistula and those who did not. TEF: Tracheoesophageal fistula.
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of proinflammatory cytokines induced by radiation[22,23]; 
this, in turn, produces edema and fibrosis in the su-
bmucosal and underlying muscular layers. These 
processes may be much more pronounced in and around 
the shrinking tumors that respond well to RT[18], which 
may explain the significant correlation between complete 
circumferential involvement and post-RT stenosis in our 
study.
Our study showed that, although pre- and post-RT 
stenosis was a prognostic factor for patients’ survival, 
complete circumference involvement rather than a 
higher radiation dose was the key contributing factor. 
In clinical practice, physicians are often tempted to 
prescribe a higher-than-standard dose of 50 Gy for 
esophageal cancer, especially when it is expected that 
the patient is unable to undergo surgical resection 
because of tumor location, poor generalized condition, 
or patient’s refusal for surgery. Our data suggests that 
patients with cervical esophageal cancer may undergo 
radiotherapy of up to 63 Gy without increasing the 
risk of radiation-induced toxicities. Since prospective 
data is lacking, our study warrants a prospective 
trial to investigate toxicity and efficacy of high-dose 
radiotherapy for cervical esophageal cancer.
In conclusion, CRC for CEC was well tolerated, 
and a higher dose was not associated with post-RT 
stenosis. Patients with complete circumferential tumor 
involvement at diagnosis require close follow-up.
ARTICLE HIGHLIGHTS
Research background
The surgical procedure for cervical esophageal cancer (CEC) is extensive, 
and concurrent chemoradiotherapy (CRT) is the preferred treatment modality. 
Although a higher-than-standard dose of 50 Gy is suggested for CEC, the 
increased dose may lead to a higher incidence of severe toxicities, such as 
ulcer, perforation and stenosis.
Research motivation
Clinical data on radiotherapy with increased dose for CEC are scarce, and 
a toxicity evaluation is required before the administration of dose-escalated 
protocols.
Research objectives
To evaluate toxicity and treatment outcome of high dose radiotherapy for 
CEC, and to determine the factors associated with post-treatment esophageal 
stenosis.
Research methods 
In this study, the authors reviewed 62 consecutive patients who received 
definitive RT for stage Ⅰ to Ⅲ cervical esophageal cancer between 2001 
and 2015. Patients (received < 45 Gy) treated for lesions below sternal notch, 
treated with palliative aim and subsequent surgical resection, or diagnosed 
with synchronous hypopharyngeal cancer were excluded. Treatment failures 
were divided into local, outfield-esophageal, and regional failures. The factors 
predictive of esophageal stenosis requiring endoscopic dilation were analyzed.
Research results
With a median follow-up of 24.3 (range, 3.4-152) mo, the 2-year local control, 
outfield esophageal control, progression-free survival, and overall survival 
(OS) rates were 78.9%, 90.2%, 49.6%, and 57.3%, respectively. Grade 1, 2, 
and 3 esophagitis occurred in 19 (30.6%), 39 (62.9%), and 4 patients (6.5%), 
respectively, without grade ≥ 4 toxicities. Sixteen patients developed post-
RT stenosis, of which 7 cases were malignant. Four patients developed 
tracheoesophageal fistula (TEF), of which 3 cases were malignant. Factors 
significantly correlated with OS were complete circumference involvement, 
stenosis at diagnosis, and occurrence of post-RT stenosis or TEF in univariate 
analysis, while stenosis at diagnosis and occurrence of post-RT stenosis or 
TEF were significant in multivariate analysis. Factors significantly correlated 
with post-RT stenosis were stage T3/4, complete circumference involvement, 
stenosis at diagnosis, and endoscopic complete response in univariate analysis, 
while complete circumference involvement was significant in multivariate 
analysis. A higher dose (≥ 60 Gy) was not associated with the occurrence of 
post-RT stenosis or TEF.
Research conclusions 
This study showed that, although pre- and post-RT stenosis was a prognostic 
factor for patients’ survival, complete circumference involvement rather than a 
higher radiation dose was the key contributing factor, and suggesting that CEC 
can be treated with higher than the current standard dose of 50 Gy. CRT for 
CEC was well tolerated, and patients with complete circumferential involvement 
require close follow-up.
Research perspectives 
The data suggests that patients with CEC may undergo radiotherapy of up to 63 
Gy without increasing the risk of radiation-induced toxicities. Since prospective 
data is lacking, our study warrants a prospective trial to investigate toxicity and 
efficacy of high-dose radiotherapy for CEC.
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